Another interesting component of candida which I hardly see mentioned here are the extracellular enzymes it secretes. Secreted aspartyl proteases (Saps) are the main category produced, and among them an important member is phospholipase. Phospholipase activity is considered a virulence factor of candida and several inhibitory susbtances have been investigated in the past few years. Phopsholipase inhibitors are thus a potential future treatment protocol for candida.
There's a new class of antifungal drugs called echinocandins. They work by inhibiting the synthesis of B-glucan in the candida cell wall. Unfortunately, they're only available intravenously in a hospital setting.